{"id":"fluticasone-propionate-salmeterol-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness/anxiety"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate binds to glucocorticoid receptors in the airway, suppressing inflammatory cytokine production and reducing mucus secretion and airway edema. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing sustained bronchodilation. The combination provides complementary effects: anti-inflammatory control from the steroid and sustained bronchodilation from the long-acting beta agonist.","oneSentence":"Fluticasone propionate is a corticosteroid that reduces airway inflammation, while salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:45.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":"Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans","enrollment":35},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT01202097","phase":"PHASE3","title":"A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":"Asthma","enrollment":334},{"nctId":"NCT06650917","phase":"PHASE1","title":"Acupoint Massage Combined With Ear Point Pressing Beans","status":"COMPLETED","sponsor":"Hai'an Hospital of TCM001","startDate":"2016-01-01","conditions":"Asthma","enrollment":120},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT03858348","phase":"","title":"A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2019-05-01","conditions":"COPD, COPD Exacerbation","enrollment":1000},{"nctId":"NCT01484210","phase":"PHASE3","title":"Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2008-03","conditions":"Asthma","enrollment":28},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT05179512","phase":"","title":"Replication of the INSPIRE Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":98278},{"nctId":"NCT04503460","phase":"PHASE4","title":"Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-07-23","conditions":"Asthma","enrollment":24},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427},{"nctId":"NCT05664061","phase":"PHASE3","title":"Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-01-30","conditions":"Asthma","enrollment":451},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT05459194","phase":"NA","title":"Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2008-10","conditions":"Asthma","enrollment":42},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT04946630","phase":"NA","title":"Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System","status":"COMPLETED","sponsor":"Inhalation Sciences Sweden AB","startDate":"2021-06-07","conditions":"Nebulizers and Vaporizers","enrollment":12},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT02474017","phase":"PHASE1","title":"An Open Study to Assess the Robustness of the CRC749 Inhaler","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2015-05","conditions":"Asthma, COPD","enrollment":111},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02980133","phase":"PHASE3","title":"Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-12-28","conditions":"Asthma","enrollment":841},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02680561","phase":"PHASE1","title":"A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-04","conditions":"Asthma","enrollment":20},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03158311","phase":"PHASE3","title":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-05","conditions":"Asthma","enrollment":1426},{"nctId":"NCT03063086","phase":"PHASE2","title":"Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-01-21","conditions":"Asthma","enrollment":116},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT02024204","phase":"NA","title":"Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-04-09","conditions":"Lung Diseases, Medication Compliance","enrollment":60},{"nctId":"NCT01117116","phase":"NA","title":"Sub-Sensitivity to Long-Acting Bronchodilators (LABA)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2010-03","conditions":"Asthma","enrollment":21},{"nctId":"NCT02826343","phase":"EARLY_PHASE1","title":"New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2016-05-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT03394989","phase":"PHASE3","title":"BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2018-10-17","conditions":"Bronchial Asthma","enrollment":1366},{"nctId":"NCT00394368","phase":"PHASE3","title":"EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-11","conditions":"Bronchial Asthma","enrollment":180},{"nctId":"NCT02571777","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-08","conditions":"Asthma","enrollment":3092},{"nctId":"NCT03676413","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-10-02","conditions":"Asthma","enrollment":451},{"nctId":"NCT03395002","phase":"PHASE4","title":"Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-22","conditions":"COPD","enrollment":58},{"nctId":"NCT03240575","phase":"PHASE4","title":"The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":302},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT02554786","phase":"PHASE3","title":"A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-29","conditions":"Asthma","enrollment":2216},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT03755544","phase":"","title":"Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-01-16","conditions":"Asthma, Chronic Obstructive Pulmonary Disease","enrollment":231},{"nctId":"NCT03535870","phase":"NA","title":"Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)","status":"COMPLETED","sponsor":"West-Ward Pharmaceutical","startDate":"2018-04-26","conditions":"Asthma","enrollment":1556},{"nctId":"NCT02251379","phase":"PHASE2","title":"Environmental Control as Add-on Therapy in Childhood Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-10-01","conditions":"Asthma","enrollment":155},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT03055988","phase":"PHASE4","title":"Cardiovascular Function in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT02202616","phase":"PHASE4","title":"Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":401},{"nctId":"NCT00830505","phase":"PHASE4","title":"Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-04","conditions":"Asthma","enrollment":38},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT03387241","phase":"PHASE3","title":"Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2017-06-02","conditions":"Asthma","enrollment":330},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT01494610","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00118716","phase":"PHASE4","title":"A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-23","conditions":"Bronchospasm, Activity/Exercise Induced Bronchospasm","enrollment":248},{"nctId":"NCT00269087","phase":"PHASE3","title":"GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":122},{"nctId":"NCT03751202","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-11-20","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT02061280","phase":"PHASE4","title":"Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2013-10","conditions":"Asthma","enrollment":108},{"nctId":"NCT03745261","phase":"PHASE3","title":"Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT01967173","phase":"PHASE3","title":"Best African American Response to Asthma Drugs","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-02","conditions":"Asthma","enrollment":574},{"nctId":"NCT01511367","phase":"PHASE3","title":"Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2012-03","conditions":"Asthma","enrollment":498},{"nctId":"NCT01342913","phase":"PHASE3","title":"A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":528},{"nctId":"NCT00984659","phase":"PHASE4","title":"Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":366},{"nctId":"NCT01462344","phase":"PHASE4","title":"6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Asthma","enrollment":6250},{"nctId":"NCT01475721","phase":"PHASE4","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-18","conditions":"Asthma","enrollment":11751},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT00355342","phase":"PHASE4","title":"Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":186},{"nctId":"NCT00395304","phase":"PHASE3","title":"Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-03","conditions":"Asthma","enrollment":182},{"nctId":"NCT03562923","phase":"PHASE3","title":"A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-10","conditions":"Asthma","enrollment":1204},{"nctId":"NCT01540708","phase":"PHASE1","title":"A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Asthma","enrollment":36},{"nctId":"NCT01890863","phase":"PHASE1","title":"ROTAHALER Device Optimization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-05","conditions":"Asthma","enrollment":36},{"nctId":"NCT00353873","phase":"PHASE4","title":"Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-18","conditions":"Asthma","enrollment":506},{"nctId":"NCT02491970","phase":"PHASE4","title":"Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol","status":"TERMINATED","sponsor":"Mundipharma Korea Ltd","startDate":"2015-08-31","conditions":"Asthma","enrollment":15},{"nctId":"NCT01706328","phase":"PHASE3","title":"A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":828},{"nctId":"NCT03238482","phase":"PHASE1","title":"Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-08-16","conditions":"Asthma","enrollment":64},{"nctId":"NCT00273026","phase":"PHASE4","title":"Study In Asthma Control","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2004-11-08","conditions":"Asthma","enrollment":680},{"nctId":"NCT03461627","phase":"PHASE3","title":"Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2017-04-01","conditions":"Asthma","enrollment":300},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT01323621","phase":"PHASE3","title":"Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":512},{"nctId":"NCT00455923","phase":"PHASE4","title":"SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-03","conditions":"Asthma","enrollment":100},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT01772134","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":617},{"nctId":"NCT02649478","phase":"NA","title":"Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2014-08","conditions":"Asthma","enrollment":1430},{"nctId":"NCT00214019","phase":"NA","title":"The Effect of Salmeterol on Eosinophil (EOS) Function","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advair®","Seretide®","Fluticasone propionate","ADVAIR","DISKUS"],"phase":"marketed","status":"active","brandName":"Fluticasone propionate/salmeterol combination","genericName":"Fluticasone propionate/salmeterol combination","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate is a corticosteroid that reduces airway inflammation, while salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}